PBM
AQST icon

Propel Bio Management’s Aquestive Therapeutics AQST Stock Holding History

Propel Bio Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6M Buy
1,442,397
+731,409
+103% +$3.08M 3.14% 11
2026
Q1 		$2.95M Buy
+710,988
New +$2.89M 1.86% 20

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Propel Bio Management's AQST Position: Q2 2026 in Review

Propel Bio Management increased its Aquestive Therapeutics (AQST) stake by 103% in Q2 2026, buying an estimated $3.08M and bringing the position to 1,442,397 shares worth $6M. The position accounts for 3.14% of the portfolio, ranked #11.

Propel Bio Management first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Propel Bio Management held 1,442,397 shares of Aquestive Therapeutics worth $6M as of Q2 2026.
  • Propel Bio Management bought 731,409 Aquestive Therapeutics shares in Q2 2026, an estimated $3.08M.
  • Aquestive Therapeutics made up 3.14% of Propel Bio Management's portfolio in Q2 2026, its #11 holding.
  • Propel Bio Management first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.